Michałek Stanisław, Maj Anna M, Gurba-Bryśkiewicz Lidia, Maruszak Wioleta, Wiśniewski Krzysztof, Zagozda Marcin, Stypik Mariola, Dubiel Krzysztof, Wieczorek Maciej
Celon Pharma S.A. ul. Marymoncka 15 05-152 Kazuń Nowy Poland
RSC Adv. 2024 Sep 6;14(39):28516-28523. doi: 10.1039/d4ra04923c. eCollection 2024 Sep 4.
Herein, we describe a two-step sequential flow synthesis: Pd-catalyzed aerobic oxidation to an aldehyde 2, which is then converted by reductive amination in H-Cube® PRO into CPL302415 (3). CPL302415 is our new PI3Kδ inhibitor, which is now under evaluation for the treatment of systemic lupus erythematosus. The process was optimized using the DoE approach and generalized to other biologically active derivatives of CPL302415.
在此,我们描述了一种两步连续流动合成方法:钯催化的需氧氧化反应生成醛2,然后在H-Cube® PRO中通过还原胺化反应将其转化为CPL302415(3)。CPL302415是我们新的PI3Kδ抑制剂,目前正在评估其用于治疗系统性红斑狼疮的效果。该工艺采用实验设计方法进行了优化,并推广至CPL302415的其他生物活性衍生物。